Response of aged parkinsonian monkeys to in vivo gene transfer of GDNF

Neurobiology of Disease

Volumn 36, Issue 2, 2009, Pages 303-311

  Emborg, M E ^a,b   Moirano, J ^a,b   Raschke, J ^a   Bondarenko, V ^a   Zufferey, R ^c   Peng, S ^a   Ebert, A D ^d   Joers, V ^a   Roitberg, B ^e   Holden, J E ^a   Koprich, J ^f   Lipton, J ^g   Kordower, J H ^h   Aebischer, P ^d  

^a UNIVERSITY OF WISCONSIN   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^f TORONTO WESTERN HOSPITAL   (Canada)

^g UNIVERSITY OF CINCINNATI   (United States)

^h RUSH MEDICAL COLLEGE   (United States)

Author keywords

Aging; GDNF; Gene transfer; Macaque; MPTP; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; BETA GALACTOSIDASE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LENTIVIRUS VECTOR;

AGED; AGING; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; IN VIVO GENE TRANSFER; MALE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PRIORITY JOURNAL; RHESUS MONKEY; TREATMENT RESPONSE; VIRAL GENE DELIVERY SYSTEM;

AGE FACTORS; AGING; ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; LENTIVIRUS; MACACA MULATTA; MALE; PARKINSONIAN DISORDERS; PSYCHOMOTOR PERFORMANCE; RECOVERY OF FUNCTION;

EID: 70349762432     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2009.07.022     Document Type: Article

References (58)

1. Ai Y., Markesbery W., Zhang Z., Grondin R., Elseberry D., Gerhardt G.A., and Gash D.M. Intraputamenal infusion of GDNF in aged rhesus monkeys: distribution and dopaminergic effects. J. Comp. Neurol. 461 (2003) 250-261
2. Bachevalier J., Landis L.S., Walker L.C., Brickson M., Mishkin M., Price D.L., and Cork L.C. Aged monkeys exhibit behavioral deficits indicative of widespread cerebral dysfunction. Neurobiol. Aging 12 (1991) 99-111
3. Bezard E. A call for clinically driven experimental design in assessing neuroprotection in experimental Parkinsonism. Behav. Pharmacol. 17 (2006) 379-382
4. Bohn M.C., and Choi-Lundberg D.L. Gene Therapies for Parkinson's Disease (1988), Humana Press, New Jersey
5. Burger C., Gorbatyuk O.S., Velardo M.J., Peden C.S., Williams P., Zolotukhin S., Reier P.J., Mandel R.J., and Muzyczka N. Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol. Ther. 10 (2004) 302-317
6. Burns R.S., Chiueh C.C., Markey S.P., Ebert M.H., Jacobowitz D.M., and Kopin I.J. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. U. S. A. 80 (1983) 4546-4550
7. Capitanio J., and Emborg M. Contributions of non-human primates to neuroscience research. Lancet 371 (2008) 1126-1135
8. Choi-Lundberg D.L., Lin Q., Chang Y.N., Chiang Y.L., Hay C.M., Mohajeri H., Davidson B.L., and Bohn M.C. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 275 (1997) 838-841
9. Collier T.J., Lipton J., Daley B.F., Palfi S., Chu Y., Sortwell C., Bakay R.A., Sladek Jr. J.R., and Kordower J.H. Aging-related changes in the nigrostriatal dopamine system and the response to MPTP in nonhuman primates: diminished compensatory mechanisms as a prelude to parkinsonism. Neurobiol. Dis. 26 (2007) 56-65
10. Conde J.R., and Streit W.J. Microglia in the aging brain. J. Neuropathol. Exp. Neurol. 65 (2006) 199-203
11. Dejesus O.T., Endres C.J., Shelton S.E., Nickles R.J., and Holden J.E. Noninvasive assessment of aromatic L-amino acid decarboxylase activity in aging rhesus monkey brain in vivo. Synapse 39 (2001) 58-63
12. Eberling J., Bankiewicz K., Jordan S., VanBrocklin H., and Jagust W. PET studies of functional compensation in a primate model of Parkinson's disease. NeuroReport 8 (1997) 2727-2733
13. Emborg M.E. Evaluation of animal models of Parkinson's disease for neuroprotective strategies. J. Neurosci. Methods 139 (2004) 121-143
14. Emborg M.E. Nonhuman primate models of Parkinson's disease. ILAR 48 (2007) 339-355
15. Emborg-Knott M.E., and Domino E.F. MPTP-Induced hemiparkinsonism in nonhuman primates 6-8 years after a single unilateral intracarotid dose. Exp. Neurol. 152 (1998) 214-220
16. Emborg M.E., Ma S.Y., Mufson E.J., Levey A.I., Taylor M.D., Brown W.D., Holden J.E., and Kordower J.H. Age-related declines in nigral neuronal function correlate with motor impairments in rhesus monkeys. J. Comp. Neurol. 401 (1998) 253-265
17. Emborg M.E., Moirano J., Schafernak K.T., Moirano M., Evans M., Konecny T., Roitberg B., Ambarish P., Mangubat E., Ma Y., Eidelberg D., Holden J., Kordower J.H., and Leestma J.E. Basal ganglia lesions after MPTP administration in rhesus monkeys. Neurobiol. Dis. 23 (2006) 281-289
18. Emborg M.E., Carbon M., Holden J.E., During M.J., Ma Y., Tang C., Moirano J., Fitzsimons H., Rothberg B.Z., Tuccar E., Roberts A., Kaplitt M.G., and Eidelberg D. Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism. J. Cereb. Blood Flow Metab. 27 (2007) 501-509
19. Eslamboli A., Cummings R.M., Ridley R.M., Baker H.F., Muzyczka N., Burger C., Mandel R.J., Kirik D., and Annett L.E. Recombinant adeno-associated viral vector (rAAV) delivery of GDNF provides protection against 6-OHDA lesion in the common marmoset monkey (Callithrix jacchus). Exp. Neurol. 184 (2003) 536-548
20. Eslamboli A., Georgievska B., Ridley R.M., Baker H.F., Muzyczka N., Burger C., Mandel R.J., Annett L., and Kirik D. Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease. J. Neurosci. 25 (2005) 769-777
21. Gash D.M., Zhang Z., Umberger G., Mahood K., Smith M., Smith C., and Gerhardt G.A. An automated movement assessment panel for upper limb motor functions in rhesus monkeys and humans. J. Neurosci. Methods 89 2 (1999) 111-117
22. Gerhardt G.A., Cass W.A., Henson M., Zhang Z., Ovadia A., Hoffer B.J., and Gash D.M. Age-related changes in potassium-evoked overflow of dopamine in the striatum of the rhesus monkey. Neurobiol. Aging 16 (1995) 939-946
23. Goldman-Rakic P.S., and Brown R.M. Regional changes of monoamines in cerebral cortex and subcortical structures of aging rhesus monkeys. Neurosci. 6 (1981) 177-187
24. Granholm A.C., Boger H., and Emborg M.E. Mood, Memory, and Movement: An Age-Related Neurodegenerative Complex?. Current Aging Science 1 (2008) 133-139
25. Grondin R., Zhang Z., Gerhardt G.A., and Gash D.M. Dopaminergic therapy improves upper limb motor performance in aged rhesus monkeys. Ann. Neurol. 48 (2000) 250-253
26. Grondin R., Zhang Z., Yi A., Cass W.A., Maswood N., Andersen A.H., Elsberry D.D., Klein M.C., Gerhardt G.A., and Gash D.M. Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. Brain 125 (2002) 2191-2201
27. Grondin R., Cass W.A., Zhang Z., Stanford J.A., Gash D.M., and Gerhardt G.A. Glial cell line-derived neurotrophic factor increases stimulus-evoked dopamine release and motor speed in aged rhesus monkeys. J. Neurosci. 23 (2003) 1974-1980
28. Hottinger A.F., Azzouz M., Déglon N., Aebischer P., and Zurn A.D. Complete and long-term rescue of lesioned adult motoneurons by lentiviral-mediated expression of glial cell line-derived neurotrophic factor in the facial nucleus. J. Neurosci. 20 (2000) 5587-5593
29. Irwin I., DeLanney L.E., McNeill T., Chan P., Forno L.S., Murphy Jr. G.M., Di Monte D.A., Sandy M.S., and Langston J.W. Aging and the nigrostriatal dopamine system: a non-human primate study. Neurodegeneration 3 (1994) 251-265
30. Kish S.J., Shannak K., and Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N. Engl. J. Med. 318 (1988) 876-880
31. Kishima H., Poyot T., Bloch J., Dauguet J., Condé F., Dollé F., Hinnen F., Pralong W., Palfi S., Déglon N., Aebischer P., and Hantraye P. Encapsulated GDNF-producing C2C12 cells for Parkinson's disease: a pre-clinical study in chronic MPTP-treated baboons. Neurobiol. Dis. 16 (2004) 428-439
32. Kojima H., Abiru Y., Sakajiri K., Watabe K., Ohishi N., Takamori M., Hatanaka H., and Yagi K. Adenovirus-mediated transduction with human glial cell line-derived neurotrophic factor gene prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopamine depletion in striatum of mouse brain. Biochem. Biophys. Res. Commun. 238 (1997) 569-573
33. Kordower J.H., Bloch J., Ma S.Y., Chu Y., Palfi S., Roitberg B.Z., Emborg M., Hantraye P., Déglon N., and Aebischer P. Lentiviral gene transfer to the non-human primate brain. Exp. Neurol. 160 (1999) 1-16
34. Kordower J.H., Emborg M.E., Bloch J., Ma S.Y., Chu Y., Leventhal L., McBride J., Chen E., Palfi S., Roitberg B., Brown D., Holden J., Pyzalski R., Taylor M., Carvey P., Ling Z., Trono D., Hantraye P., Deglon N., and Aebischer P. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290 (2000) 767-773
35. Korell M., and Tanner C. Epidemiology of Parkinson's Disease: An Overview (2005), Boca Raton
36. Kozlowski D.A., Connor B., Tillerson J.L., Schallert T., and Bohn M.C. Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections. Exp. Neurol. 166 (2000) 1-15
37. Kurlan R., Kim M.H., and Gash D.M. Oral levodopa dose-response study in MPTP-induced hemiparkinsonian monkeys: assessment with a new rating scale for monkey parkinsonism. Mov. Disord. 6 (1991) 111-118
38. Langston J.W., Forno L.S., Rebert C.S., and Irwin I. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey. Brain Res. 292 (1984) 390-394
39. Lin L.F., Doherty D.H., Lile J.D., Bektesh S., and Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260 (1993) 1130-1132
40. Mandel R.J., Snyder R.O., and Leff S.E. Recombinant adeno-associated viral vector-mediated glial cell line-derived neurotrophic factor gene transfer protects nigral dopamine neurons after onset of progressive degeneration in a rat model of Parkinson's disease. Exp. Neurol. 160 (1999) 205-214
41. McGeer P., Schwab C., Parent A., and Doudet D. Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. Ann. Neurol. 54 (2003) 599-604
42. Morrish P.K., Sawle G.V., and Brooks D.J. Clinical and [18F] dopa PET findings in early Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 59 (1995) 597-600
43. O'Callaghan J., Miller D., and Reinhard J. Characterization of the origins of astrocytes response to injury using the dopamine neurotoxicant, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine. Brain Res. 521 (1990) 73-80
44. Ovadia A., Zhang Z., and Gash D.M. Increased susceptibility to MPTP toxicity in middle-aged rhesus monkeys. Neurobiol. Aging 16 (1995) 931-937
45. Sandell J., and Peters A. Effects of age on nerve fibers in the rhesus monkey optic nerve. J. Comp. Neurol. 429 (2001) 541-553
46. Sautter J., Tseng J.L., Braguglia D., Aebischer P., Spenger C., Seiler R.W., Widmer H.R., and Zurn A.D. Implants of polymer-encapsulated genetically modified cells releasing glial cell line-derived neurotrophic factor improve survival, growth, and function of fetal dopaminergic grafts. Exp. Neurol. 149 (1998) 230-236
47. Sheffield L.G., and Berman N.E. Microglial expression of MHC class II increases in normal aging of nonhuman primates. Neurobiol. Aging 19 (1998) 47-55
48. Sherer T.B., Fiske B.K., Svendsen C.N., Lang A.E., and Langston J.W. Crossroads in GDNF therapy for Parkinson's disease. Mov. Disord. 21 (2006) 136-141
49. Siddiqi Z.A., and Peters A. The effect of aging on pars compacta of the substantia nigra in rhesus monkey. J. Neuropathol. Exp. Neurol. 58 (1999) 903-920
50. Stephenson D.T., Meglasson M.D., Connell M.A., Childs M.A., Hajos-Korscok E., and Emborg M.E. The effects of a selective dopamine D2 receptor agonist on behavioral and pathological outcome in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated squirrel monkeys. J. Pharmacol. Exp. Ther. 314 (2005) 1257-1266
51. Tanner C.M., and Ben-Shlomo Y. Epidemiology of Parkinson's disease. Adv. Neurol. 80 (1999) 153-159
52. Tseng J.L., Baetge E.E., Zurn A.D., and Aebischer P. GDNF reduces drug-induced rotational behavior after medial forebrain bundle transection by a mechanism not involving striatal dopamine. J. Neurosci. 17 (1997) 325-333
53. Turrentine F., Wang H., Simpson V.B., and Jones R.S. Surgical risk factors, morbidity, and mortality in elderly patients. J. Am. Coll. Surg. 203 (2006) 865-877
54. Walker M.L., and Herndon J.G. Menopause in nonhuman primates?. Biol. Reprod. 79 (2008) 398-406
55. Wenk G.L., Pierce D.J., Struble R.G., Price D.L., and Cork L.C. Age-related changes in multiple neurotransmitter systems in the monkey brain. Neurobiol. Aging 10 (1989) 11-19
56. Zhang Z., Andersen A., Smith C., Grondin R., Gerhardt G., and Gash D. Motor slowing and parkinsonian signs in aging rhesus monkeys mirror human aging. J. Gerontol. A Biol. Sci. Med. Sci. 55 (2000) B473-B480
57. Zufferey R., Nagy D., Mandel R.J., Naldini L., and Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nature Biotech. 15 (1997) 871-875
58. Zufferey R., Donello J.E., Trono D., and Hope T.J. Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J. Virol. 73 (1999) 2886-2892